Patents-Review.com
ClassID:

21255 ⎘

A61K45/05 - CPC Classification

Classification description:

Medicinal preparations containing active ingredients not provided for in groups  -  Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer

Recent Application in this class:
#1
20260048075
2026-02-19

Inhibition of TCF4/ITF2 in the Treatment of Cancer

 #2
20260041795
2026-02-12

ADENO-ASSOCIATED VIRUS CAPSID HAVING TISSUE TROPISM AND USE THEREOF

 #3
20250345397
2025-11-13

IL-15 MUTANT-Fc/IL-15R ALPHA SUBUNIT-Fc HETERODIMER AND USE THEREOF

 #4
20250230226
2025-07-17

PLXDC1/PLXDC2 ACTIVATORS AND THEIR USE IN THE TREATMENT OF BLOOD VESSEL DISORDERS

 #5
20240368307
2024-11-07

METHODS AND COMPOSITIONS FOR TREATING SEPSIS

 #6
20240358760
2024-10-31

Primary T-Cell Expansion

 #7
20240335473
2024-10-10

USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1ALPHA) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS)

 #8
20240307337
2024-09-19

Method Of Treatment Of Obesity

 #9
20240066096
2024-02-29

pH-triggered membrane peptide-mediated epitope tethering at cell surfaces

 #10
20240066064
2024-02-29

METHODS AND COMPOSITIONS FOR GENE EDITING IN HEMATOPOIETIC STEM CELLS

 #11
20230285462
2023-09-14

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #12
20230285461
2023-09-14

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #13
20230285460
2023-09-14

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #14
20230263830
2023-08-24

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #15
20230241115
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #16
20230241114
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #17
20230241113
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #18
20230241112
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #19
20230241110
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #20
20230241109
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #21
20230241108
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #22
20230233612
2023-07-27

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #23
20230137548
2023-05-04

NEURAL STEM CELL-MEDIATED CANCER TREATMENT

 #24
20230119171
2023-04-20

BIOMARKER PANELS FOR STRATIFICATION OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN CANCER

 #25
20220403007
2022-12-22

Cancer Neoepitopes

 #26
20220125901
2022-04-28

TREATMENT OF CANCER USING RECALL ANTIGENS DELIVERED BY ATTENUATED BACTERIA

 #27
20220049021
2022-02-17

FLT3L-Fc FUSION PROTEINS AND METHODS OF USE

 #28
20220000922
2022-01-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #29
20210401892
2021-12-30

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #30
20210386846
2021-12-16

NOVEL METHODS FOR INDUCING AN IMMUNE RESPONSE

 #31
20210353548
2021-11-18

Oral dosage form

 #32
20210338735
2021-11-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #33
20210338734
2021-11-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #34
20210330708
2021-10-28

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #35
20210260120
2021-08-26

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #36
20210253707
2021-08-19

GM-CSF/CD40L VACCINE AND CHECKPOINT INHIBITOR COMBINATION THERAPY

 #37
20210251932
2021-08-19

Method of treatment of obesity

 #38
20210244765
2021-08-12

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #39
20210213064
2021-07-15

Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers

 #40
20210145888
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #41
20210145887
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #42
20210145886
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #43
20210137986
2021-05-13

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #44
20210137985
2021-05-13

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #45
20210113619
2021-04-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #46
20210100845
2021-04-08

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #47
20210093669
2021-04-01

Primary T-cell expansion

 #48
20210087244
2021-03-25

Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide

 #49
20210087243
2021-03-25

Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide

 #50
20210070887
2021-03-11

FLT3L-FC fusion proteins

 #51
20210069251
2021-03-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #52
20210060150
2021-03-04

NOVEL ADENOVIRUS

 #53
20210060078
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #54
20210060077
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #55
20210060074
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #56
20210052654
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #57
20210052653
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #58
20210052652
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #59
20210052651
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #60
20210038678
2021-02-11

Compositions comprising cyclic peptides derived from an A-beta peptide

 #61
20210009718
2021-01-14

FLT3L-Fc FUSION PROTEINS AND METHODS OF USE

 #62
20210008206
2021-01-14

ADENOSINE PATHWAY INHIBITORS FOR CANCER TREATMENT

 #63
20210008149
2021-01-14

WNT5A PEPTIDES IN REDUCTION OF CANCER STEM CELLS

 #64
20210000916
2021-01-07

Composition comprising poly I:C and LAG-3-IGG fusion protein

 #65
20200360433
2020-11-19

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #66
20200323919
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #67
20200323918
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #68
20200323916
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #69
20200323915
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #70
20200323914
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #71
20200323913
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #72
20200323911
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #73
20200323910
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #74
20200323909
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #75
20200323907
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #76
20200323906
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #77
20200306311
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #78
20200306308
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #79
20200306305
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #80
20200297772
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #81
20200297771
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #82
20200297770
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #83
20200297647
2020-09-24

Oral dosage form

 #84
20200281975
2020-09-10

Methods and compositions for gene editing in hematopoietic stem cells

 #85
20200268800
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #86
20200268799
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #87
20200268798
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #88
20200261506
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #89
20200261505
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #90
20200261504
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #91
20200222465
2020-07-16

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #92
20200206268
2020-07-02

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #93
20200197441
2020-06-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #94
20200179454
2020-06-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #95
20200179453
2020-06-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #96
20200171091
2020-06-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #97
20200163996
2020-05-28

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #98
20200155605
2020-05-21

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #99
20200155604
2020-05-21

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #100
20200140831
2020-05-07

Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy

 #101
20200108097
2020-04-09

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #102
20200093862
2020-03-26

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #103
20200085874
2020-03-19

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #104
20200085873
2020-03-19

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #105
20200038453
2020-02-06

Neural stem cell-mediated cancer treatment

 #106
20200038448
2020-02-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #107
20200038447
2020-02-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #108
20200038446
2020-02-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #109
20200023038
2020-01-23

METHOD OF TREATING NEOPLASIAS

 #110
20190328826
2019-10-31

Compositions and methods for treating cancer and persistent viral infections

 #111
20190314461
2019-10-17

Composition and method for treating nucleic acid-related eye disease

 #112
20190307796
2019-10-10

Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (TILS)

 #113
20190298776
2019-10-03

Amnion coated embolic agents for treating tumors

 #114
20190255164
2019-08-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #115
20190255113
2019-08-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #116
20190255112
2019-08-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #117
20190255110
2019-08-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #118
20190231829
2019-08-01

Compositions and methods for treating immune disorders using immune modulating bacteria strains

 #119
20190231666
2019-08-01

ANTI-DANDRUFF COMPOSITION

 #120
20190218515
2019-07-18

EX VIVO BITE-ACTIVATED T CELLS

 #121
20190204302
2019-07-04

Quantitative ligandomics for systematic identification of therapeutic ligands

 #122
20190184196
2019-06-20

FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF

 #123
20190183912
2019-06-20

Antiviral prodrugs of tenofovir

 #124
20190175609
2019-06-13

THERAPEUTIC USES OF A C-RAF INHIBITOR

 #125
20190151401
2019-05-23

Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide

 #126
20190105295
2019-04-11

Method of treatment of obesity

 #127
20190083546
2019-03-21

Methods and materials for treating tumors

 #128
20180369355
2018-12-27

Targeting of ligand binding sites in ClfA

 #129
20180346535
2018-12-06

Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide

 #130
20180326027
2018-11-15

EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE ANTIBODIES THERETO

 #131
20180319856
2018-11-08

Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide

 #132
20180318421
2018-11-08

Methods for the treatment of recurrent glioblastoma (RGBM)

 #133
20180264015
2018-09-20

Leukocyte infiltration promoting agent and antitumor immunostimulatory agent

 #134
20180250375
2018-09-06

Methods for inducing an immune response

 #135
20180250339
2018-09-06

Methods and compositions for gene editing in hematopoietic stem cells

 #136
20180162943
2018-06-14

GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy

 #137
20180161433
2018-06-14

SIZE TUNABLE MICROBIAL MIMETICS FOR IMMUNOTHERAPY OF THYROID CARCINOMAS AND SOLID TUMORS

 #138
20180141998
2018-05-24

Cancer neoepitopes

 #139
20180140657
2018-05-24

Compositions and methods for treating cancer and persistent viral infections

 #140
20180125936
2018-05-10

METHOD OF TREATING NEOPLASIAS

 #141
20180117075
2018-05-03

Therapy for malignant disease

 #142
20180104320
2018-04-19

Treatment of cancer using recall antigens delivered by attenuated bacteria

 #143
20180078613
2018-03-22

MACROPHAGE ACTIVATING FACTOR FOR TREATING BENIGN OR PRECANCEROUS PAPILLOMAS

 #144
20180071362
2018-03-15

Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein

 #145
20170360760
2017-12-21

Inhibitors of bromodomains

 #146
20170333731
2017-11-23

Formulations of histone deacetylase inhibitor and uses thereof

 #147
20170319693
2017-11-09

Treatment of cornea using laminin

 #148
20170312284
2017-11-02

Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activating enzyme ATG7

 #149
20170291934
2017-10-12

IMPROVED THERAPEUTIC CONTROL OF HETERODIMERIC AND SINGLE CHAIN FORMS OF INTERLEUKIN-12

 #150
20170106057
2017-04-20

Composition and method for treating nucleic acid-related eye disease

 #151
20170095510
2017-04-06

Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders

 #152
20150010524
2015-01-08

Composition and method for treating nucleic acid-related eye disease

 #153
20140057862
2014-02-27

Formulations of histone deacetylase inhibitor and uses therof

 #154
20140056964
2014-02-27

GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING

 #155
20110311624
2011-12-22

Formulations of histone deacetylase inhibitor and uses thereof

 #156
20090082444
2009-03-26

Compositions for the Treatment of Blood Disorders

 #157
20050032731
2005-02-10

Oligoribonucleotides alert the immune system of animals to the imminence of microbial infection